121 related articles for article (PubMed ID: 24378132)
1. [Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].
Zhou H; Wang JY; Tan Y; Lü HY; Wang M; Cai QC; Zhang HZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):920-3. PubMed ID: 24378132
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
[TBL] [Abstract][Full Text] [Related]
4. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
Levy C; Taha MK; Bingen E; Cohen R;
Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
[TBL] [Abstract][Full Text] [Related]
6. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
7. [Meningococcemia and meningitis due to Neisseria meningitidis W135 developed in two cases vaccinated with bivalent (A/C) meningococcal vaccine].
Turhan V; Acar A; Kılıç A; Budak S; Oncül O; Haznedaroğlu T; Görenek L
Mikrobiyol Bul; 2010 Jul; 44(3):473-8. PubMed ID: 21063998
[TBL] [Abstract][Full Text] [Related]
8. [Study on immunogenicity of group A and group C meningococcal conjugate vaccine with coupling group B meningococcal outer membrane protein].
Ma FB; Tao H; Wang HJ
Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):451-5. PubMed ID: 20084975
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
Badahdah AM; Rashid H; Khatami A
Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.
Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R
Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042
[TBL] [Abstract][Full Text] [Related]
11. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
12. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
13. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
15. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
[TBL] [Abstract][Full Text] [Related]
16. [Bacterial meningitis caused by Neisseria meningitidis. Prophylactic measures].
Magdzik W
Przegl Epidemiol; 2004; 58(2):241-51. PubMed ID: 15521103
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.
Joseph H; Ryall R; Bybel M; Papa T; MacLennan J; Buttery J; Borrow R
J Infect Dis; 2003 Apr; 187(7):1142-6. PubMed ID: 12660929
[TBL] [Abstract][Full Text] [Related]
18. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
19. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
[TBL] [Abstract][Full Text] [Related]
20. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
